Colorectal Cancer

The FDA has accepted for review an sBLA for adjuvant atezolizumab plus chemotherapy in stage III dMMR/MSI-H colon cancer.

Need a refresh on the current regulatory landscape for GI oncology? We have it covered. Here's everything that moved the needle across GI malignancies this month.

In the phase 3 RECITE trial, romiplostim significantly reduced chemotherapy dose modifications due to thrombocytopenia vs placebo in gastrointestinal cancers.

Jennifer Eads, MD, discusses data for the CAR T-cell therapy CHM-2101 in relapsed/refractory GI cancers.

CIRCULATE provides the first prospective randomized evidence in support of a ctDNA-guided treatment escalation strategy in pMMR/MSS stage II colon cancer.

Encorafenib plus cetuximab and FOLFIRI improved PFS vs chemotherapy alone in first-line BRAF V600E–mutant metastatic colorectal cancer.

Marwan G. Fakih, MD, discusses the synergy between liquid and tissue biopsies and the need for a data-driven approach to repeat ctDNA testing in CRC.

Marwan G. Fakih, MD, discusses the pitfalls of using liquid TMB for immunotherapy selection and the need for tissue-liquid biopsy concordance in CRC.

The European Medicines Agency’s CHMP has issued a positive opinion for encorafenib plus cetuximab and mFOLFOX6 in first-line BRAF V600E–mutant mCRC.

Marwan G. Fakih, MD, outlines situations when ctDNA and tissue NGS agree, when they diverge, and scenarios that should prompt repeat liquid biopsy testing.

CHMP recommended trastuzumab deruxtecan for HER2-positive (IHC 3+) metastatic solid tumors, marking the first tumor-agnostic ADC opinion in the EU.

The FDA approved Dato-DXd for PD-1/PD-L1–ineligible triple-negative breast cancer, granted priority review to sevabertinib in HER2-mutant NSCLC, and more.

The FDA has granted fast track designation to suplexa in MSI-H CRC.

Polls highlighted key abstracts of interest from the upcoming ASCO Annual Meeting.

Colton Jones, MD, shares data from a retrospective analysis of GLP-1 receptor agonists vs aspirin for the primary prevention of colorectal cancer.

Pelareorep plus bevacizumab and FOLFIRI showed a 33% response rate and 19.5-month median response duration in RAS-mutant MSS CRC.

The top 5 OncLive TV videos of the week cover insights in multiple myeloma, HER2+ breast cancer, pancreatic cancer, colorectal cancer, and melanoma.

Colton Jones, MD, discusses real-world data comparing GLP-1 receptor agonists and aspirin for the primary prevention of colorectal cancer.

Ozekibart plus FOLFIRI produced ORRs that exceed historical benchmarks for standard later-line CRC regimens.

Translational analyses from NEOPRISM-CRC also link ctDNA clearance/kinetics and TCR clonality with pCRs, supporting biomarker-guided treatment selection.

Colton Jones, MD, and Joel Saltzman, MD, discuss the potential role of GLP-1 receptor agonists in CRC prevention based on retrospective data.

Experts highlight ctDNA-guided strategies, ADCs, and targeted therapies shaping CRC research in the first quarter of 2026.

Christopher Lieu, MD, discusses the need for global collaboration and interdisciplinary research to address the rise of early-onset CRC.

The FDA grants full approval to brexu-cel in mantle cell lymphoma, grants priority review to a lirafugratinib NDA in FGFR2+ pretreated cholangiocarcinoma, and more.

John L. Marshall, MD, discusses how the clinical reality of early-onset CRC in young, fit patients contradicts traditional lifestyle-based assumptions.